Changes in ambulatory glucose profile in people with type 1 diabetes using an automated insulin delivery system - two year follow-up retrospective analysis of real-world data

被引:1
|
作者
Mueller-Korbsch, Michael [1 ]
Kietaibl, Antonia [2 ]
Haufe, Yves [3 ]
Fasching, Peter [2 ]
机构
[1] MedVienna Arztezentrum, Sensengasse 3-1-1-3, A-1090 Vienna, Austria
[2] 5th Med Dept, Med Dept 5, Vienna, Austria
[3] Dexcom Deutschland GmbH, Mainz, Germany
来源
关键词
Automated insulin delivery; Diabetes mellitus type 1; Diabetes technology; Open-source AID;
D O I
10.1016/j.deman.2023.100150
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The number of available automated insulin delivery (AID) systems is increasing in Austria and people with diabetes (PwD) replace sensor-augmented pump (SAP) therapy more and more frequently. The present study is the two years follow-up of our prior monocentric, retrospective analysis conducted between 2019 and 2021, comparing SAP and open-source AID systems in people with type 1 diabetes. This second-year analysis included 25 PwD and investigated glycemic changes based on ambulatory glucose profiles (AGP). In comparison to the first year, a worsening of mean glucose (125.4 to 135.2 mg/dl, P = 0.038), time in range ((TIR), 84.2 to 77.0%, P = 0.012), time above range ((TAR), 11.6% to 18.5%, P = 0.017) and glycemia risk index ((GRI), 24.8 to 35.0%, P = 0.026) was observed. The reduction of mean glucose and glucose variability with AID in the first year was due to a significant decrease in time in hyperglycemia with resulting higher TIR and lower GRI. In this second-year follow up, TIR and GRI showed a significant deterioration, a familiar phenomenon in diabetology. However, open-source AID systems showed continuous safety, as there was no increase in time below range (TBR) even after two years. Despite the slight deterioration in the glycemic parameters, open-source AID systems were able to demonstrate sufficient glycemic control according to international consensus guidelines while offering the characteristic benefits of a reduced burden of diabetes management. A descriptive comparison of different AID algorithms indicated an improved glycemic control with more advanced features such as basal rate modification, auto bolus function and autotuning. (c) 2023 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
引用
收藏
页数:3
相关论文
共 50 条
  • [41] Real-world glycaemic outcomes of >12,200 adults with type 1 diabetes using the Omnipod® 5 Automated Insulin Delivery (AID) system with cloud-based data management
    Wilmot, E. G.
    Lal, R. A.
    Aleppo, G.
    Huyett, L. M.
    Snow, K.
    Mendez, J. J.
    Hadjiyianni, I.
    Ly, T. T.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S119 - S120
  • [42] Real-World Glycemic Outcomes of >5,900 Adults with Type 1 Diabetes Using the Omnipod 5 Automated Insulin Delivery (AID) System with Cloud-Based Data Management
    Lal, Rayhan
    Aleppo, Grazia
    Huyett, Lauren M.
    Snow, Kenneth
    Mendez, Jose J.
    Hadjiyianni, Irene
    Ly, Trang T.
    DIABETES, 2023, 72
  • [43] The expression of particular glucose transporters and insulin resistance indicators in the risk groups of type 2 diabetes - a two-year follow-up
    Bemat-Karpinska, Malgorzata
    Piatkiewicz, Pawel
    Czech, Anna
    Wierzbicki, Piotr
    ENDOKRYNOLOGIA POLSKA, 2012, 63 (03) : 212 - 219
  • [44] A COMPARISON OF GLYCEMIC VARIABILITY IN CSII VS MDI IN PEOPLE WITH TYPE 1 DIABETES: A REAL-WORLD DATA ANALYSIS
    Mourad, S.
    Irshad, M.
    Baqer, A.
    Azizieh, M.
    Al Kandari, J.
    Al Ozairi, E.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2023, 25 : A188 - A188
  • [45] Real-World Glycemic Outcomes of >400 Adults with Type 2 Diabetes Using the Omnipod 5 Automated Insulin Delivery (AID) System with Cloud-Based Data Management
    Peters, Anne L.
    Pasquel, Francisco J.
    Huyett, Lauren M.
    Snow, Kenneth
    Mendez, Jose J.
    Hadjiyianni, Irene
    Ly, Trang T.
    DIABETES, 2023, 72
  • [46] A 15-Year Follow-up Retrospective Study on 959 Spine Surgeries What Can We Learn From Real-world Data?
    Plazier, Mark
    Raymaekers, Vincent
    Bruyneel, Luk
    Coeckelberghs, Ellen
    Sermeus, Walter
    Vanhaecht, Kris
    Duyvendak, Wim
    CLINICAL SPINE SURGERY, 2021, 34 (05): : E282 - E288
  • [47] Real-world safety profile of once-weekly semaglutide in people with type 2 diabetes: Analysis of pooled data from the SemaglUtide Real-world Evidence (SURE) programme
    Yale, Jean-Francois
    Major-Pedersen, Atheline
    Catarig, Andrei-Mircea
    Jain, Rashmi
    Menzen, Markus
    Holmes, Patrick
    DIABETES OBESITY & METABOLISM, 2024, 26 (10): : 4429 - 4440
  • [48] Real-world evidence on clinical outcomes of people with type 1 diabetes using open-source and commercial automated insulin dosing systems: A systematic review
    Knoll, Christine
    Peacock, Sofia
    Waldchen, Mandy
    Cooper, Drew
    Aulakh, Simran Kaur
    Raile, Klemens
    Hussain, Sufyan
    Braune, Katarina
    DIABETIC MEDICINE, 2022, 39 (05)
  • [49] Real-World Glycemic Outcomes of >3,300 Children and Adolescents with Type 1 Diabetes Using the Omnipod 5 Automated Insulin Delivery (AID) System with Cloud-Based Data Management
    Sherr, Jennifer
    Desalvo, Daniel
    Huyett, Lauren M.
    Snow, Kenneth
    Mendez, Jose J.
    Hadjiyianni, Irene
    Ly, Trang T.
    DIABETES, 2023, 72
  • [50] Glucose Management Indicator results: real-world data of 3,510 patients with type 1 diabetes using a tubeless insulin pump with continuous glucose monitoring
    Ly, T. T.
    Jantz, J.
    Zheng, Y.
    He, J.
    Benjamin, E.
    Layne, J.
    DIABETOLOGIA, 2019, 62 : S389 - S389